

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2023

**Genelux Corporation**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-41599  
(Commission  
File Number)

77-0583529  
(I.R.S. Employer  
Identification No.)

2625 Townsgate Road, Suite 230  
Westlake Village, California  
(Address of principal executive offices)

91361  
(Zip Code)

Registrant's telephone number, including area code: (805) 267-9889

Not Applicable  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.001 per share	GNLX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On June 27, 2023, Genelux Corporation (the “Company”) made available the slide presentation attached hereto as Exhibit 99.1 (the “Corporate Presentation”). Information from the Corporate Presentation may also be used by the management of the Company in future meetings regarding the Company. For important information about forward-looking statements in the Corporate Presentation, see the slide titled “Forward-Looking Statements” in Exhibit 99.1 attached hereto.

The information contained or incorporated in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

**Item 8.01 Other Events.**

As noted in Item 7.01, on June 27, 2023, the Company made available the Corporate Presentation.

In the Corporate Presentation, the Company announced that:

- Enrollment for the Company’s Phase 3 registration clinical trial for its lead product candidate, Olvi-Vec, in platinum-resistant/refractory ovarian cancer is expected to be completed as early as mid-2024, with 11-month follow-up;
- Initial interim data for the Company’s Phase 2 clinical trial for Olvi-Vec in recurrent non-small-cell lung cancer in the United States is expected as early as mid-2024; and
- The Company currently expects its cash operating runway to extend into the first quarter of 2026.

**Cautionary Note Regarding Forward-Looking Statements**

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are subject to the “safe harbor” created by those sections. These forward-looking statements consist of statements regarding: (i) the Company’s expectations regarding the timing and interim data for its Phase 2 and Phase 3 clinical trials for Olvi-Vec and (ii) the Company’s expectations regarding its cash operating runway. Actual future results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, without limitation: the accuracy of the Company’s assumptions and expectations underlying its projections regarding its cash operating runway; uncertainty regarding geopolitical and macroeconomic events and any resulting delays in clinical trials; risks associated with the discovery, development and regulation of Olvi-Vec; the risk that the Company or its partners may cease or delay preclinical or clinical development activities for any existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials); the possibility that existing collaborations could be terminated early; subsequent study or trial results and findings may contradict earlier study or trial results and findings; and the risks set forth under “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and in the Company’s other filings with the Securities and Exchange Commission. The forward-looking statements are applicable only as of the date on which they are made, and the Company does not assume any obligation to update any forward-looking statements, except as may be required by law.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Slide presentation, dated June 27, 2023</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Genelux Corporation**

Date: June 27, 2023

By: /s/ Thomas Zindrick, J.D.

Thomas Zindrick, J.D.

President and Chief Executive Officer

---



Corporate Presentation | June 2023

---

# Forward Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections, about Genelux Corporation (“Genelux,” the “Company,” “we,” “us” or “our”) that are based on the beliefs and assumptions of our management team, and on information currently available to such management team. These forward-looking statements include, but are not limited to, statements concerning: Olvi-Vec’s potential utility and our plans and expectations for Olvi-Vec across various designs and indications; our expectations regarding the field of oncolytic viral immunotherapy; Olvi-Vec’s potential to provide utility across multiple tumor types, and our expectations regarding our Phase 3 trial; our clinical trial strategy and design; our expectations regarding (i) the timing of our Phase 2 and Phase 3 clinical trials and (ii) our intellectual property rights under the Newsora license agreement; our planned investments to meet worldwide clinical trial demand and facilitate our U.S. commercial launch; the commercial market opportunity for Olvi-Vec in the United States; our various commercial strategies for self-launching Olvi-Vec for ovarian cancer in the United States, including expected milestones related to clinical trials and commercial partnerships and collaborations; and our expectations regarding our cash operating runway. These forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control. All statements, other than statements of historical fact, contained in this presentation, including statements regarding future events, future financial performance, business strategy and plans, and objectives of ours for future operations, are forward-looking statements.

Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, and in our other filings with the SEC, which may cause our actual results, levels of activity, performance or achievements of and those of our industry to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on any forward-looking statement. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all. Except as required by law, Genelux does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Trade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this presentation appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.

This presentation discusses a product candidate that is under clinical study and which has not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of this product candidate for the use for which it is being studied.

---

# Highlights of Genelux Execution

---



## **Olvi-Vec: De-risked late-stage Clinical Program**

Ongoing pivotal trial in late-stage Ovarian Cancer and planned Phase 2 trial Adjuvant Maintenance NSCLC



## **CHOICE™ Platform; Broad and Diverse Discovery Engine**

Library with over 500 novel vaccinia strains and 110+ transgenes



## **Validating Strategic Partnerships**

Newsoara Biopharma (Greater China rights) initiating three Phase 1/2 clinical trials with Olvi-Vec and ELIAS Animal Health (global rights) initiating canine efficacy studies with V-VET1



## **Focused Commercial Strategy**

US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights



## **Estimated Billion Dollar Plus Market Opportunity in the U.S.**

Potential beyond this in numerous clinical settings

# The Most Advanced Non-local Delivery Oncolytic Immunotherapy

*Olvi-Vec: Engineered to selectively target and eliminate tumor cells while inducing a robust patient-specific immune response*



## Physician-preferred Routes of Delivery

- Regional and systemic administration to preferentially locate, colonize and destroy tumor cells
- Potential utility in multiple cancers (demonstrated in 20 pre-clinical tumor models), including metastatic disease



## Antitumor Effect and Well Tolerated

- Strong data in Phase 1b/2 study in platinum-resistant/refractory ovarian cancer (PRROC)
- No Maximum Tolerated Dose (MTD) observed



## Ideal Backbone of Combination Therapy

- Turns tumors “hot” by localized inflammation and induction of the influx of tumor infiltrating lymphocytes (TILs)
- Positively modulates anti-tumor pathways in tumor microenvironment

# Diversified Designs and Indications Exploit Competitive Advantages

Olvi-Vec	Human Health	Design	Preclinical	Phase 1	Phase 2	Phase 3	Collaborators
<b>Regional Route</b>	<b>Ovarian Cancer</b> <i>(platinum-resistant/refractory)</i>	<b>Olvi-Vec (I.pe) + Chemotherapy</b>	<b>Ph3 OnPrime/GOG-3076 Study Actively Enrolling</b>				<b>GOG FOUNDATION</b> <i>(Cooperative Group)</i>
<b>Systemic Route</b>	<b>Non-Small Cell Lung Cancer</b> <i>(Adjuvant Maintenance)</i>	<b>Olvi-Vec (IV) + Chemotherapy</b>	<b>Ph2 Preparing</b>				<b>NEWSGARA</b> <i>(Greater China)</i>
	<b>Small Cell Lung Cancer</b> <i>(recurrent)</i>	<b>Olvi-Vec (IV) + Chemotherapy</b>	<b>Ph1b/2 enrolling</b>				
	<b>Ovarian Cancer</b> <i>(recurrent)</i>	<b>Olvi-Vec (IV) + Chemotherapy</b>	<b>Ph1b/2 Planned</b>				
	<b>Non-Small Cell Lung Cancer</b> <i>(relapsed/recurrent)</i>	<b>Olvi-Vec (IV) + Chemotherapy</b>	<b>Regulatory Submission</b>				
<b>V2ACT Immunotherapy</b>			<b>Preclinical</b>	<b>Phase 1</b>	<b>Phase 2</b>	<b>Phase 3</b>	
<b>Systemic Route</b>	<b>Pancreatic Cancer</b>	<b>Olvi-Vec (IV) + Adoptive Cell Therapy</b>	<b>Regulatory Submission</b>				<b>VACT</b> <i>(Worldwide Rights Ex-Greater China)</i>
<b>V-VET1</b>	<b>Animal Health</b>		<b>Safety</b>	<b>Preliminary Efficacy</b>	<b>Pivotal Efficacy</b>		
<b>Systemic Route</b>	<b>Hematologic and solid tumors</b>	<b>V-VET1 (IV) +/- standard of care</b>	<b>Preparing</b>				<b>ELIAS</b> <i>(Worldwide)</i>



# Selective Replication In Tumors Unleashes Immune System Against Cancer


## Key Takeaways

*Olvi-Vec is a robust immune modulator that utilizes a triple mode of action to mount a personalized attack against cancer cells throughout the body*

- Kills cancer cells directly
- Enhances (neo)antigen presentation and stimulates a tumor-specific immune response
- Converts tumor microenvironment from immunosuppressive (cold state) to immunoreactive (hot state)

### Olvi-Vec

viral infection



**Oncolysis and release of tumor (neo)antigens**



#### 'Cold' tumor before Olvi-Vec

- No or relatively low number of immune effector cells
- Relatively high number of immune suppressor cells

#### Innate Immune Activation

- Increase Type I IFNs
- Increase DAMPs / PAMPs



#### Adaptive Immune Activation

- APCs present (neo)antigens
- T-cell activation & cytotoxicity
- Anti-tumor immune memory




#### 'Hot' tumor following Olvi-Vec immunotherapy

- Increase of proinflammatory cytokines/chemokines
- Influx of CD8+ effector T cells
- M2 to M1 transition of tumor-associated macrophages
- Decrease of immune suppression
- Changes of tumor gene expression profile
- Immunogenic tumor cell death
- Reverse platinum-resistance and synergy with other therapies
- Vascular collapse

PAMPs - Pathogen-associated Molecular Patterns  
DAMPs - Damage-associated Molecular Patterns

# Olvi-Vec-Primed Immunotherapy: Overcoming Drug Resistance



# Over \$4 Billion in Transactions in Active Oncolytic Space

## Emerging Late-Stage Modality

With its recent IPO, Genelix joined the public markets as a Phase 3 company

A maturing field with Amgen launching Imlygic in 2014 and Phase 3 companies (CGO, Replimune, GNLX) working to validate its power and potential




CG Oncology raises \$120 million in Series E financing to advance clinical-stage urologic oncology pipeline



Replimune completed a \$225 million offering as well as \$200M in non-dilutive debt financing



Genelix enters the public markets raising \$68.5M in the first half of 2023












# Competitive Advantages of Olvi-Vec as an Oncolytic Virus

## Key Takeaways

### **Olvi-Vec Key Advantages:**


- Broad spectrum of activity
- Tumor selectivity
- Strong lytic activity / spread
- Strong immune activator
- Engineering capability
- Multiple routes of delivery
- Nonhuman pathogen
- Stable DNA virus
- Cytoplasmic, no genomic integration

## Oncolytic Virus Space

Key Players and Assets	Olvi-Vec Key Advantages
 <b>Olvi-Vec</b>	 Target & Treat Metastatic Disease
 Herpes	 Systemic Delivery and redosing
 Herpes	 Robust Immune Activation Profile
 Herpes	 Target & Treat Tumors of Various Size
 Adenovirus	
 Reovirus	

IV dosing is the physician preferred administration technique, and our IV data has the potential to enable physician preferred administration vs. local-delivery-only assets

# Creating a New Paradigm Of Oncolytic Virus Drug Development



## Olvi-Vec

### Our New Generation

Olvi-Vec has the potential to redefine the oncolytic virus space and provide utility across multiple tumor types by enabling physician-preferred administration techniques and setting new benchmarks in efficacy and safety, as shown in multiple clinical trials. Genelux looks to its Phase 3 trial to potentially bring a best-in-class therapy to those patients in need.

### 1<sup>st</sup> Gen Viruses

Commercial/Late-stage 1st Generation viruses confirm modality's potential, but all are limited to local delivery and scope of addressable cancers

# Phase Ib: Anti-tumor Activity as Monotherapy Leading into Combination

## Patient Background & Study Treatment

Platinum-resistant / refractory ovarian cancer

- Heavily pre-treated patients with documented progressive disease at baseline
- Single cycle of high & condensed bolus infusions (intraperitoneal delivery) on 2 consecutive days; total dose:  $6 \times 10^9$  pfu

## *Olvi-Vec Monotherapy (11 patients)*



### Tolerability:

- No Dose Limiting Toxicity (DLT)
- No Maximum Tolerated Dose (MTD)
- No Grade 4 Adverse Events (AE)



### Antitumor activity:

- Clinical Benefit Rate: 73% (8/11)
- 4/11 patients had >2x PFS relative to immediate prior chemotherapy




### Translational Evidence:

- Activation of tumor-specific T cell response detected in blood
- Documented immune activation in tumor microenvironment with significant influx of TILs
- Favorable immune-related genetic signatures

Manyam et al., Gynecologic Oncology 163 (2021) 481 - 489

# Completed Phase 2 Tested Olvi-Vec Immunochemotherapy

## Olvi-Vec Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer



Results of the VIRO-15 Phase 2 Trial were published in JAMA Oncology ([Link](#))

# Clinically-Meaningful Responses in Heavily Pretreated Patients

## Key Clinical Takeaways

### **Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC**

- All patients had documented progressive disease at enrollment
- Overall response rate in 27 patients was 54% with 7.6-month median duration of response
- Historical PFS in this patient population is ~4 mos

## Overall Response Rate (ORR) & Progression-Free Survival (PFS)\*

	ORR by RECIST1.1**	Duration of Response	ORR by CA-125	Median PFS	Median OS
<b>All patients (n= 27)</b> (95% CI)	<b>54%</b> (13 <sup>§</sup> /24) (33 - 74)	<b>7.6 mos</b> (3.7 - 9.6)	<b>85%</b> (22/26) (65 - 96)	<b>11.0 mos</b> (6.7 - 13.0)	<b>15.7 mos</b> (12.3 - 23.8)
<b>Platinum-resistant (n=14)</b> (95% CI)	<b>55%</b> (6/11) (26 - 84)	<b>7.6 mos</b> (3.7 - NA)	<b>85%</b> (11/13) (55 - 98)	<b>10.0 mos</b> (6.4 - NA)	<b>18.5 mos</b> (11.3 - 23.8)
<b>Platinum-refractory (n=13)</b> (95% CI)	<b>54%</b> (7/13) (27 - 81)	<b>8.0 mos</b> (3.7 - NA)	<b>85%</b> (11/13) (55 - 98)	<b>11.4 mos</b> (4.3 -13.2)	<b>14.7 mos</b> (10.8 - 33.6)

\*Baseline for ORR & PFS evaluation is the timepoint immediately prior to starting post-Oliv-Vec carboplatin doublet +/- bevacizumab to allow direct comparison to historical data or patients' own previous line of chemotherapy

\*\*Eligible for evaluation: with at least 1 measurable target lesion at baseline; including 2 patients without post-chemo scan after virotherapy, and therefore are assigned to the 'inevaluable for response' category per RECIST1.1

§Including 3 unconfirmed; 2 in resistant and 1 in refractory groups



# Demonstrated Deep and Durable Tumor Shrinkage

## Key Clinical Takeaways

### Refractory patients performed as well as resistant patients



#### Tumor Shrinkage

- Overall, 86% of PRROC patients showed tumor reduction, with 91% of Platinum-refractory patients showing tumor reduction

- Four patients had 100% reduction of target lesions (two with confirmed CR), including two platinum-refractory patients

#### Duration of Response (DOR)

- DOR of 7.6 Months in all platinum-Resistant patients
- DOR of 8.0 Months in platinum-refractory patients



# Olvi-Vec-Primed Immunochemotherapy Overcomes "Refractoriness"

Exemplary platinum-refractory patients, after platinum re-challenge, achieved *PFS exceeding any prior lines*

## 15B-01:

- Stage IIIB papillary serous
- ECOG: 0
- BRCA negative
- PD-L1 negative


## 15B-15:

- Stage IIIB high-grade serous
- ECOG: 0
- BRCA negative
- PD-L1 negative


## 15B-17:

- Stage IIIC high-grade serous
- ECOG: 1
- BRCA negative


Overall Survival: 23.2 Months



Overall Survival: 12.3 Months



Overall Survival: 15.7 Months




# Durable Benefit of Overall Survival via Clinically-Validated Endpoint

## Key Clinical Takeaways

### **20% long-term survivors consistent with commercially successful immunotherapies**

- Historical data in 4th line and beyond shows a median overall survival of only 9.8 months
- On a median 5th line of treatment, VIRO-15 Ph2 patients achieved a mOS of 15.7 mos
- 4 of 6 long-term survivors were platinum-refractory at enrollment




# "Allcomers" Approach May Reset Life Clock of Heavily Pre-treated Patients

## Key Trial Takeaways

### **Olvi-Vec addresses a broad and underserved pool of patients**

- Olvi-Vec trial inclusion criteria allows patients regardless of (i) tumor biomarkers, (ii) platinum refractory tumors or (iii) number of prior lines of treatment (i.e., no cap)
- Olvi-Vec Phase 2 results approach results in less pre-treated platinum-sensitive patients

While clinical remissions are obtainable, a majority of patients will relapse. Genelux looks to take an all-comers approach




Study	# or prior lines	Regimen
<b>Platinum-resistant / refractory patients</b>		
AURELIA <sup>1</sup>	≤ 2 prior lines	Chemo + Avastin (i.e., CT+Bev)
B-GEMOX <sup>2</sup>	1-2 (21%), 3-4 (63%), ≥ 5 (16%)	Oxali + Gem + Avastin
FORWARD II <sup>3</sup>	Median 3 prior lines	Mirvetuximab soravtansine + pembrolizumab (median/high FRα group)
VB-111 <sup>4</sup>	≤ 3 prior lines	VB-111 + paclitaxel
JAVELIN-200	≤ 3 prior lines	Avelumab + PLD
TOPACIO <sup>5</sup>	≤ 4 prior lines	Niraparib + pembrolizumab
<b>Genelux (VIRO-15)</b>	<b>Median 4 prior lines</b>	<b>Olvi-Vec / Chemo ± Avastin</b>
<b>Platinum-sensitive patients</b>		
OCEANS <sup>6</sup>	No prior chemo in recurrent setting	Carbo + Gem + Avastin

References  
 (1) Pujade-Lauraine et al., J Clin Oncol 2014;32:1302-1306. (3) Matulis et al., ESMO 2018.  
 (2) Ikeda et al., Int J Gynecol Cancer 2013;23:355-360. (4) Arend et al., Gynecol Oncol. 2020;157:578-584. (5) Konstantinopoulos et al., J Clin Oncol 2018;36(S15):106.  
 (6) Aghajanian et al., Gynecol Oncol. 2015;139(1):10-16.

Footnote: As the data presented is based on a cross-trial comparison and not a head-to-head clinical trial, such comparisons may not be reliable due to differences in study protocols, conditions and patient populations. Accordingly, cross-trial comparisons may not be reliable predictors of the relative efficacy or other characteristics of our candidates compared to others presented.

# Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results

Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment



*A platinum resensitizing agent is a long-standing desirable and highly demanded mechanism of action of Gyn-Oncs, their so-call "Holy Grail".\**

\*Journal of Investigative Medicine High Impact Case Reports, Volume 6: 1-3, 2018  
DOI: 10.1177/2324709618760080 J journals.sagepub.com/home/hic


# Systemic administration demonstrated dose-dependent OS benefit

## Key Trial Takeaways

### Demonstrated feasibility and clinical benefit of multiple IV cycles

- Median 5 prior lines of therapy
- **Regimen:** various dosing levels and schedules (typically over 4-6 months)
- **Well tolerated:** no-MTD reached with one DLT
- **Clinical Benefit:** statistically significant overall survival (OS) benefit in primary and metastatic lung diseases

## Dose Escalation Phase 1b Monotherapy Study in Solid Tumors Progressed from Last Prior Therapy



## Key Trial Takeaways

### Anti-tumor effect of IV Immunochemotherapy


- High and Condensed Dosing (single cycle: bolus infusion on 5 consecutive days)
- Well tolerated: No DLT or MTD reached
- Monotherapy: Anti-tumor effects
- Combination therapy: Virus treatment revitalized tumors to subsequent chemotherapy with prolonged PFS and OS

### Recurrent metastatic cervical cancer

#### with lung mets

Case Report (Pt. #21A-06)

- ❖ Received 5 consecutive daily i.v. doses
  - Transient adverse reactions: fever, nausea, bone pain (Hx arthritis)
  - Stable disease with no tumor size increase




- ❖ Chemotherapy after disease progression
  - Partial Response
  - PFS: 70+ Weeks
  - OS: 53.4 Months

### High-grade pancreatic cancer with

#### lung & liver mets

Case Report (Pt. #21A-04)

- ❖ Received 5 consecutive daily i.v. doses
  - Transient adverse reactions: fever, nausea
  - 59% drop of CA19.9 tumor biomarker and Objective Response per RECIST, with PFS of 18 weeks



- ❖ Chemotherapy after disease progression
  - 83% drop of CA 19.9
  - Partial Response by RECIST
  - PFS: 31 wks

# Genelux has Partnered with Newsoara BioPharma Co., Ltd



**Benny Li, PhD**  
**Founder and Chief Executive Officer**  
20+ yrs. global and China local pharma  
Former VP, GM of Takeda China  
Development Center and SVP, Executive  
GM of R&D at Hansoh Pharmaceuticals  
Former Head of Clinical Development &  
Medical Affairs in Asia at Alcon/Novartis

## NEWSOARA HIGHLIGHTS

**7**  
Pipelines  
**12**  
Indications

**5**  
Phase IIb/III  
**2**  
Phase II

**\$850**  
Million Valuation

**Top 10**  
Blue-chip Biotech  
Investors

**2023**  
IPO Planned

Newsoara has paid \$11M to date and GNLX is eligible for additional development, regulatory and sales milestone payments and up to mid-double-digit percentages royalties on net sales





# Validating Industry Collaboration with Newsoara BioPharma Co., Ltd

## Key Takeaways

- Newsoara will fully fund the US-based Genelux Phase 2 trial in NSCLC
- Newsoara has development and commercialization rights in Greater China
- Phase 2 in NSCLC initial interim readouts expected as early as mid-2024

## Systemic Program: Clinical Trials

Sponsor	Trial Sites	Indication	Clinical Stage	Patients (est.)	Randomization
	US	Adjuvant Maintenance NSCLC	Phase II	~138	2:1
	China	Recurrent OC	Phase I/II	~150	2:1
		Recurrent NSCLC	Phase I/II	~150	2:1
		Recurrent SCLC	Phase I/II	~150	Single arm

Genelux will have worldwide commercial rights (excluding Greater China) to all data generated from clinical trials of Olvi-Vec in China.



V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT.

Vaccination increases the numbers of neoantigen-specific T cells in the body and Olvi-Vec kills cancer cells and potentiates T cells by increasing cancer tissue receptivity to adoptively transferred neoantigen-specific effector T cells.

## Key Trial Takeaways

### **V2ACT Immunotherapy, combines an oncolytic immunotherapy and adoptive cell therapy**

- Induces an acute inflammatory response in the tumor and converts tumor microenvironment from immunosuppressive to immunostimulatory;
- Anticipated to enhance effect of neoantigen specific effector T cells

Technology	TVI Adoptive Cell Therapy	Olvi-Vec Oncolytic Immunotherapy
Patients Dosed	~ 130	~ 150
Regulatory	Fast Track Designation / FDA Grant - glioblastoma	Phase 3 enrolling - ovarian

Novel IO modality: United States Patent No. 11,633,442, issued in April 2023

# Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch

## Key Takeaways


- Established and equipped an independent, Company-controlled 7,500+ Sq. Ft manufacturing facility in San Diego to secure material for pivotal studies and potential commercial supply
- cGMP material manufactured and released for the ongoing Phase 3 Trial and Newsöara's trials
- Planned investment to augment internal development capabilities as well as continually improve proprietary manufacturing processes
- Genelux aims to meet worldwide clinical trial demand and U.S. commercial launch

## Large-Scale cGMP Manufacturing Process to Optimize Production



Facilities and Operations: Based in Southern California

# Estimated Billion Dollar Plus Olvi-Vec Commercial Opportunity (US)



**Ovarian Cancer Market<sup>1</sup>**

**~\$1.8B** in 2022, expected CAGR growth ~23.5%

**~233,000** women in the US currently<sup>2</sup>



**70-80%** will relapse

### Drivers of Market Penetration

- The Phase 3 population is a broad category of patients with significant unmet medical need, including those excluded from other therapies or trials.

## Self Launch Olvi-Vec for Ovarian Cancer in the US



### Partnerships

Leverage partnership with GOG Foundation

- Preeminent US-based cooperative group in Gynecologic Oncology
- Composed of leading KOLs in the field
- Partners in the OnPrime/GOG-3076 Phase 3 registration trial



### Self-Manufacturing

Large-Scale cGMP Manufacturing

- Control of Production Schedule
- Attractive COGs
- Ability to scale up modular process



### Patients

Population without Standard of Care

- PRROC patients lack effective SoC therapies
- Limited number of Gyn-Oncs enabling specialty sales team
- Label expansion starting with IV administration in 2L ovarian (Ph2 planned)




### Reimbursement

Compelling Value Proposition for Payors

- Significant unmet medical need
- No SOC
- Combination with generic/biosimilars

# Choice Platform Library: 500+ Vectors with 110+ Transgenes



✓ *In vitro* & *in vivo* tested: GLP Tox ready

## Immune Modularity Molecules

- IL-6/sIL-6R
- IL-24

## Cell Growth & Differentiation Regulators

- BMP-4

## Cell Matrix-Degradative Genes

- hMMP9

## Clonal Isolated Strains (non-GMO)

- LIVP1.1
- LIVP5.1.1
- V-VET1 (LIVP6.1.1)
- Cop15.1.1

## Single-Chain Antibodies

- Anti-VEGF
- Anti-PD-1
- Anti-FAP
- Anti-PD-L1
- Anti-DLL4
- Anti-CTLA4
- Anti- $\alpha\beta$ 3-integrin

## Intellectual Property: Market Exclusivity & Freedom to Operate

---



Patent Portfolio: 39 issued patents;  
Olvi-Vec covered by Composition of Matter  
(2031) and Manufacturing (2038)



Olvi-Vec: Worldwide operating freedom;  
No third-party royalties due



Long Duration of Regulatory / Marketing  
Exclusivity



# Accomplished Leadership Team

## Executive Team



**Thomas Zindrick, JD**  
Chief Executive Officer  
AMGEN  
aeromics DNX



**Paul Scigalla, MD, PhD**  
Chief Medical Officer  
Pfizer  
NEUOLUTION PRC



**Doug Samuelson**  
Chief Financial Officer  
SECONDSIGHT  
AdvaVet edacta USA



**Sean Ryder, JD**  
General Counsel  
HELSINN  
mesoblast

## Operations & R&D



**Tony Yu, PhD**  
SVP, ClinDev  
UC San Diego  
MOORE'S CANCER CENTER



**Joseph Cappello, PhD**  
Chief Technical Officer  
THE UNIVERSITY OF UTAH  
BRAUN  
SHIMBUI COPOLYMER



**Qian Zhang, MD, PhD**  
VP, Clinical Sciences  
UC San Diego  
MOORE'S CANCER CENTER



**Caroline Jewett**  
Head, Quality  
AMGEN



**Ralph Smalling**  
Head, Regulatory Affairs  
AMGEN



**Cathy Gust**  
VP, Program Mgmt  
AMGEN

## Board of Directors

**THOMAS ZINDRICK, JD**  
Chairman of the Board



**JAMES L. TYREE, MBA**  
Lead Independent Director



**MARY MIRABELLI, MBA**  
Director



**JOHN THOMAS, MBA, PhD**  
Director



**GABRIEL WOODWARD**  
Director






# Genelux Has Executed on Multiple Milestones and is Positioned for the Future

## Executed Milestones

- ✓ Executed on go public strategy and follow on with \$60M raised
- ✓ Initiation of Phase 3 Trial in PRROC
- ✓ Phase 2 results published in JAMA Oncology
- ✓ Collaboration and License agreement with Newsoara
- ✓ Initiation of Phase 1b/2 trial in recurrent SCLC (China)
- ✓ Issuance of V2ACT US Patent



# Expected Operating Runway into 1Q 2026

## Capitalization Summary

Stock Symbol	<b>GNLX</b>
Share Price <sup>(1)</sup>	<b>\$35.00</b>
Shares Outstanding	<b>25.85M</b>
Market Capitalization <sup>(1)</sup>	<b>\$892M</b>
Cash & Equivalents <sup>(2)</sup>	<b>\$28.04M</b>
PIPE Commitments Due	<b>\$ 27.5M<sup>***</sup></b>
Insider Ownership FULLY DILUTED	<b>30.9%</b>

1) At market close on June 16<sup>th</sup>, 2023.  
 2) As of June 16<sup>th</sup>, 2023.

## Analyst Coverage

- **Bruce Jackson** M.S., MBA  
The Benchmark Company
- **Kemp Dolliver** CFA  
BROOKLINE CAPITAL MARKETS

2023 Financing Events  
 January IPO: \$15M  
 May Private Placement<sup>\*\*</sup>: \$33M  
 June Private Placement<sup>\*\*\*</sup>: \$18M

\*Reconciliation of Cap Table and Balance Sheet:  
 -All Preferred Series (1400 A-K investors) to Common  
 -\$32M (debt and accrued dividends) to Common

\*\* Includes \$15M that two investors will, and are contractually obligated to, fund no later than November 15, 2023

\*\*\* Includes \$12.5M that one investor will, and are contractually obligated to, fund no later than November 15, 2023

# Highlights of Genelux Execution

---



## **Olvi-Vec: De-risked late-stage Clinical Program**

Ongoing pivotal trial in late-stage Ovarian Cancer and planned Phase 2 trial Adjuvant Maintenance NSCLC



## **CHOICE™ Platform; Broad and Diverse Discovery Engine**

Library with over 500 novel vaccinia strains and 110+ transgenes



## **Validating Strategic Partnerships**

Newsoara Biopharma (Greater China rights) initiating three Phase 1/2 clinical trials with Olvi-Vec and ELIAS Animal Health (global rights) initiating canine efficacy studies with V-VET1



## **Focused Commercial Strategy**

US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights



## **Estimated Billion Dollar Plus Market Opportunity in the U.S.**

Potential beyond this in numerous clinical settings

The logo for GENELUX features the word "GENELUX" in a bold, black, sans-serif font. The letter "G" is stylized with a green dot and is enclosed within a green, horizontal, oval shape that tapers at both ends. The background of the slide is a light green gradient with faint, white, circular patterns and a glowing, wireframe globe on the right side.

**GENELUX**

*Redefining Immuno-Oncology*

Corporate Presentation | June 2023

---